Page last updated: 2024-12-07

2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2H-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, N-oxide: structure given in first source; a potassium channel opener [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131974
CHEMBL ID93539
SCHEMBL ID4260665
MeSH IDM0225661

Synonyms (14)

Synonym
CHEMBL93539
ym 934
2-(3,4-dihydro-2,2-dimethyl-6-nitro-2h-1,4-benzoxazin-4-yl)pyridine n-oxide
2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide
ym-934
2,2-dimethyl-6-nitro-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine
136544-11-1
z0e489238b ,
unii-z0e489238b
2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(1-oxido-2-pyridinyl)-
GOTJEXSHEQBBSV-UHFFFAOYSA-N
SCHEMBL4260665
DTXSID90159834
Q27294834

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The drug was well tolerated, with headache being the only significant adverse event."( A phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers.
Burggraaf, J; Cohen, AF; Schoemaker, RC; Terpstra, IJ, 1998
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" No significant changes in routine laboratory and pharmacodynamic parameters occurred between placebo and active drug treatment."( A phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers.
Burggraaf, J; Cohen, AF; Schoemaker, RC; Terpstra, IJ, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (88.24)18.2507
2000's2 (11.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.22 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]